GTII Green Thumb Industries Inc.
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, tinctures, edibles, topicals, capsules, tinctures, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, RYM, and RHYTHM brands. It distributes its products to third-party licensed retail customers; and sells finished products to third-party licensed retail cannabis stores. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Green Thumb Industries (CNSX: GTII)
›
Green Thumb Industries (CNSX: GTII) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 5,000 employees.
The shares were at 8.740 CAD on 13 November 2026, down 22.8% over 52 weeks. Its 52-week range is 7.400 CAD to 14.39 CAD: the price is 39.3% below the high and 18.1% above the low.
At a market capitalisation of 1.92B CAD, it trades at 15.1 times trailing earnings and 15.7 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 25.0, a discount of 40% for GTII.
Green Thumb Industries reports return on equity of 6.0%, an operating margin of 8.4% and revenue up 11.3% year over year.
Its debt exceeds its cash by 238.50M USD, a debt-to-equity ratio of 0.27. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.48 CAD is 145.8% above the current price. The next earnings report is expected on 24 February 2027.